Viatris Receives FDA Approval for Once-Weekly Contraceptive Patch Gwyn Lo™
Viatris Inc. announced on July 29, 2026, that it has received U.S. FDA approval for Gwyn Lo™, a once-weekly contraceptive patch. The product offers a low-dose estrogen combined hormonal contraceptive option.
PITTSBURGH – Viatris Inc. (Nasdaq: VTRS) announced on July 29, 2026, that it has received approval from the U.S. Food and Drug Administration (FDA) for Gwyn Lo™, a new contraceptive patch. The patch provides women with a low-estrogen, once-weekly hormonal contraceptive option.
The approval represents a significant step in Viatris' efforts to advance women's health and expand its contraceptive offerings in the U.S. market. Gwyn Lo™ is designed to offer convenience and efficacy in combined hormonal contraception.
The company stated that the product increases options for women seeking hormonal birth control and is indicated for the prevention of pregnancy. Viatris, which operates in animal health and human health services, aims to continuously develop and introduce new solutions for health issues.
This latest approval for Viatris reinforces its commitment to women's health, providing consumers with a new method of contraception. Specific details regarding the product's availability or launch strategy in the United States following the approval were not immediately provided by the company.